Somatostatin receptor subtype 4 couples to the M-current to regulate seizures.
The K(+) M-current (I(M), Kv7) is an important regulator of cortical excitability, and mutations in these channels cause a seizure disorder in humans. The neuropeptide somatostatin (SST), which has antiepileptic properties, augments I(M) in hippocampal CA1 pyramidal neurons. We used SST receptor knock-out mice and subtype-selective ligands to investigate the receptor subtype that couples to I(M) and mediates the antiepileptic effects of SST. Using pentylenetetrazole as a chemoconvulsant, SST(2), SST(3), and SST(4) receptor knock-out mice all had shorter latencies to different seizure stages and increased seizure severity when compared with wild-type mice. However, the most robust differences were observed in the SST(4) knock-outs. When seizures were induced by systemic injection of kainate, only SST(4) knock-outs showed an increase in seizure sensitivity. We next examined the action of SST and subtype-selective SST agonists on electrophysiological parameters in hippocampal slices of wild-type and receptor knock-out mice. SST(2) and SST(4) appear to mediate the majority of SST inhibition of epileptiform activity in CA1. SST lacked presynaptic effects in mouse CA1, in contrast to our previous findings in rat. SST increased I(M) in CA1 pyramidal neurons of wild-type and SST(2) knock-out mice, but not SST(4) knock-out mice. Using M-channel blockers, we found that SST(4) coupling to M-channels is critical to its inhibition of epileptiform activity. This is the first demonstration of an endogenous enhancer of I(M) that is important in controlling seizure activity. SST(4) receptors could therefore be an important novel target for developing new antiepileptic and antiepileptogenic drugs.
Qiu
Cuie
C
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19348, USA.
Zeyda
Thomas
T
Johnson
Brian
B
Hochgeschwender
Ute
U
de Lecea
Luis
L
Tallent
Melanie K
MK
D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D004558:Electric Stimulation / Q000379:methods; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000503:physiopathology; D066298:In Vitro Techniques; D007608:Kainic Acid; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D008565:Membrane Proteins / Q000172:deficiency / Q000502:physiology*; D051379:Mice; D018345:Mice, Knockout; D009154:Mutation / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D018408:Patch-Clamp Techniques / Q000379:methods; D010433:Pentylenetetrazole; D011188:Potassium / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D051381:Rats; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D017481:Receptors, Somatostatin / Q000145:classification / Q000172:deficiency / Q000502:physiology*; D012640:Seizures / Q000139:chemically induced / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*
D008565:Membrane Proteins; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D017481:Receptors, Somatostatin; C098681:somatostatin receptor subtype-4; D011188:Potassium; D007608:Kainic Acid; D010433:Pentylenetetrazole